2013
DOI: 10.1158/2159-8290.cd-13-0123
|View full text |Cite
|
Sign up to set email alerts
|

Discovering What Makes STAT Signaling TYK in T-ALL

Abstract: Summary: RNA interference screening establishes TYK2 dependence in T-cell acute lymphoblastic leukemia (T-ALL), leading to identification of TYK2-activating mutations and increased IL-10 receptor signaling in T-ALL cell lines. Cancer Discov; 3(5); 494–6. ©2013 AACR. See related article by Sanda et al., p. 564

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2014
2014
2016
2016

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 11 publications
0
2
0
Order By: Relevance
“…STAT3 responds to factors including IL-6, IL-10, and vascular endothelial growth factor and is involved in T-helper cell 17 (Th17) and Treg cell development and tumorigenesis (Lin et al, 2013;Nieminen et al, 2013). STAT4 and STAT6 control Th1 and Th2 cell differentiation in response to IL-12 and IL-4/13, respectively (Fontan and Melnick, 2013;Meisch et al, 2013;Singh et al, 2013). Due to the large involvement of STATs in a variety of cell processes, it is critical that their activity be tightly regulated.…”
Section: Discussionmentioning
confidence: 99%
“…STAT3 responds to factors including IL-6, IL-10, and vascular endothelial growth factor and is involved in T-helper cell 17 (Th17) and Treg cell development and tumorigenesis (Lin et al, 2013;Nieminen et al, 2013). STAT4 and STAT6 control Th1 and Th2 cell differentiation in response to IL-12 and IL-4/13, respectively (Fontan and Melnick, 2013;Meisch et al, 2013;Singh et al, 2013). Due to the large involvement of STATs in a variety of cell processes, it is critical that their activity be tightly regulated.…”
Section: Discussionmentioning
confidence: 99%
“…19 Since TYK2 mutations are so rare in T-ALL patients, the second explanation seems more likely. In general, given the high frequency of JAK1, JAK2, and JAK3 mutations, the very low frequency of TYK2 aberrations in the entire spectrum of hematologic malignancies is highly intriguing.…”
mentioning
confidence: 99%